Alisa D Kjaergaard1, Julia S Johansen1, Stig E Bojesen1, Børge G Nordestgaard2. 1. From the Copenhagen General Population Study, Department of Clinical Biochemistry (A.D.K., S.E.B., B.G.N.), and Department of Medicine and Oncology (J.S.J.), Herlev University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (A.D.K., J.S.J., S.E.B., B.G.N.); and The Copenhagen City Heart Study, Frederiksberg University Hospital, Frederiksberg, Denmark (S.E.B., B.G.N.). 2. From the Copenhagen General Population Study, Department of Clinical Biochemistry (A.D.K., S.E.B., B.G.N.), and Department of Medicine and Oncology (J.S.J.), Herlev University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (A.D.K., J.S.J., S.E.B., B.G.N.); and The Copenhagen City Heart Study, Frederiksberg University Hospital, Frederiksberg, Denmark (S.E.B., B.G.N.). boerge.nordestgaard@regionh.dk.
Abstract
BACKGROUND AND PURPOSE: We tested the hypothesis that observationally and genetically elevated YKL-40 is associated with elevated lipids and lipoproteins and with increased risk of ischemic vascular disease. METHODS: We conducted cohort and Mendelian randomization studies in 96 110 individuals from the Danish general population, with measured plasma levels of YKL-40 (n=21 647), plasma lipids and lipoproteins (n=94 461), and CHI3L1 rs4950928 genotype (n=94 579). RESULTS:From 1977 to 2013, 3256 individuals developed ischemic stroke, 5629 ischemic cerebrovascular disease, 4183 myocardial infarction, and 10 271 developed ischemic heart disease. The 91% to 100% versus 0% to 33% YKL-40 percentile category was associated with a 34% increase in triglycerides, but only with minor changes in other lipids and lipoproteins. For these categories, the multifactorially adjusted hazard ratio was 1.99 (95% confidence interval, 1.49-2.67) for ischemic stroke, 1.85 (1.44-2.37) for ischemic cerebrovascular disease, 1.28 (0.95-1.73) for myocardial infarction, and 1.23 (1.01-1.51) for ischemic heart disease. When compared with rs4950928 CC homozygosity, the presence of G-allele was associated with a doubling (GC) or tripling (GG) in YKL-40 levels, but not with triglyceride levels or with risk of ischemic vascular disease. A doubling in YKL-40 was associated with a multifactorially adjusted observational hazard ratio for ischemic stroke of 1.18 (1.11-1.27), and a genetic odds ratio of 1.04 (0.95-1.15). Corresponding risk estimates were 1.15 (1.09-1.22) observationally and 1.06 (0.99-1.14) genetically for ischemic cerebrovascular disease, 1.08 (1.00-1.15) observationally and 1.04 (0.96-1.13) genetically for myocardial infarction, and 1.07 (1.02-1.12) observationally and 1.01 (0.96-1.07) genetically for ischemic heart disease. CONCLUSIONS:Elevated YKL-40 was associated with a 34% increase in triglyceride levels and with a 2-fold increased risk of ischemic stroke, whereas genetically elevated YKL-40 were not.
RCT Entities:
BACKGROUND AND PURPOSE: We tested the hypothesis that observationally and genetically elevated YKL-40 is associated with elevated lipids and lipoproteins and with increased risk of ischemic vascular disease. METHODS: We conducted cohort and Mendelian randomization studies in 96 110 individuals from the Danish general population, with measured plasma levels of YKL-40 (n=21 647), plasma lipids and lipoproteins (n=94 461), and CHI3L1rs4950928 genotype (n=94 579). RESULTS: From 1977 to 2013, 3256 individuals developed ischemic stroke, 5629 ischemic cerebrovascular disease, 4183 myocardial infarction, and 10 271 developed ischemic heart disease. The 91% to 100% versus 0% to 33% YKL-40 percentile category was associated with a 34% increase in triglycerides, but only with minor changes in other lipids and lipoproteins. For these categories, the multifactorially adjusted hazard ratio was 1.99 (95% confidence interval, 1.49-2.67) for ischemic stroke, 1.85 (1.44-2.37) for ischemic cerebrovascular disease, 1.28 (0.95-1.73) for myocardial infarction, and 1.23 (1.01-1.51) for ischemic heart disease. When compared with rs4950928 CC homozygosity, the presence of G-allele was associated with a doubling (GC) or tripling (GG) in YKL-40 levels, but not with triglyceride levels or with risk of ischemic vascular disease. A doubling in YKL-40 was associated with a multifactorially adjusted observational hazard ratio for ischemic stroke of 1.18 (1.11-1.27), and a genetic odds ratio of 1.04 (0.95-1.15). Corresponding risk estimates were 1.15 (1.09-1.22) observationally and 1.06 (0.99-1.14) genetically for ischemic cerebrovascular disease, 1.08 (1.00-1.15) observationally and 1.04 (0.96-1.13) genetically for myocardial infarction, and 1.07 (1.02-1.12) observationally and 1.01 (0.96-1.07) genetically for ischemic heart disease. CONCLUSIONS: Elevated YKL-40 was associated with a 34% increase in triglyceride levels and with a 2-fold increased risk of ischemic stroke, whereas genetically elevated YKL-40 were not.
Authors: Martina C de Knegt; Jesper J Linde; Andreas Fuchs; Børge G Nordestgaard; Lars V Køber; Jens D Hove; Klaus F Kofoed Journal: Int J Cardiovasc Imaging Date: 2016-07-04 Impact factor: 2.357
Authors: Shorena Janelidze; Joakim Hertze; Henrik Zetterberg; Maria Landqvist Waldö; Alexander Santillo; Kaj Blennow; Oskar Hansson Journal: Ann Clin Transl Neurol Date: 2015-11-20 Impact factor: 4.511
Authors: Jakob Schroder; Janus Christian Jakobsen; Per Winkel; Jørgen Hilden; Gorm Boje Jensen; Ahmad Sajadieh; Anders Larsson; Johan Ärnlöv; Marina Harutyunyan; Julia S Johansen; Erik Kjøller; Christian Gluud; Jens Kastrup Journal: J Am Heart Assoc Date: 2020-03-02 Impact factor: 5.501